Tysabri and Urinary bladder sarcoma - a phase IV clinical study of FDA data

Summary:

Urinary bladder sarcoma is reported only by a few people who take Tysabri.

The phase IV clinical study analyzes which people take Tysabri and have Urinary bladder sarcoma. It is created by eHealthMe based on reports of 210,327 people who have side effects while taking Tysabri from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

210,327 people reported to have side effects when taking Tysabri.
Among them, 2 people (0.0%) have Urinary bladder sarcoma.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 210,824 Tysabri users for its effectiveness, alternative drugs and more.

What is Urinary bladder sarcoma?

Urinary bladder sarcoma (urinary bladder cancer) is found to be associated with 16 drugs and 5 conditions by eHealthMe.

Number of Tysabri and Urinary bladder sarcoma reports submitted per year:

Could Tysabri cause Urinary bladder sarcoma?

Time on Tysabri when people have Urinary bladder sarcoma *:

Gender of people who have Urinary bladder sarcoma when taking Tysabri *:

female: 100 %
male: 0.0 %

Age of people who have Urinary bladder sarcoma when taking Tysabri *:

Common side effects people have besides Urinary bladder sarcoma *:

Urinary Tract Infection: 2 people, 100.00%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 100.00%
Ovarian Cancer (cancer of ovary): 2 people, 100.00%
Intestinal Mass: 2 people, 100.00%
Gastric Cancer (stomach cancer): 2 people, 100.00%
Colon Cancer: 2 people, 100.00%
Blood Urine Present: 2 people, 100.00%
Neoplasm Malignant (cancer tumour): 1 person, 50.00%
Death: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and have Urinary bladder sarcoma?

Check whether Urinary bladder sarcoma is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Urinary bladder sarcoma and when was it recovered:

Urinary bladder sarcoma in Tysabri

Expand to all the drugs that have ingredients of natalizumab:

Urinary bladder sarcoma and drugs with ingredients of natalizumab

Alternative drugs to, pros and cons of Tysabri:

Tysabri (210,824 reports)

Common Tysabri side effects:

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Urinary bladder sarcoma treatments and more:

Urinary bladder sarcoma (26 reports)

COVID vaccines that are related to Urinary bladder sarcoma:

All the drugs that are associated with Urinary bladder sarcoma:

Urinary bladder sarcoma (16 drugs)

All the conditions that are associated with Urinary bladder sarcoma:

Urinary bladder sarcoma (5 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.